CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth

CareDx (CDNA) raised its 2026 revenue guidance to $520M-$530M and lifted its adjusted EBITDA outlook to $90M-$100M after Q3 results, with transplant testing demand leading the upgrade.

The driver: transplant testing volumes rose 21% to 50,750. Management framed that volume strength as the basis for the higher outlook.

The specialty oncology unit, NavDx, added $12.5M in Q3 revenue, up 37% year over year. That gives CDNA a second growth engine alongside core transplant testing.

Management is also preparing two new molecular diagnostics, AlloHeme and HistoMap Kidney, for commercialization in 2027. The company is targeting higher reimbursement rates per test as part of its approach. Interpretation: if pricing per test improves while volumes keep climbing at a double-digit clip, the EBITDA range of $90M-$100M could prove conservative, though the article gives no per-test pricing figures to confirm that.